Sector News

AbbVie’s $21B buyout puts Pharmacyclics execs in line for $4B payoff

March 24, 2015
Life sciences
Pharmacyclics CEO Robert Duggan would add $3.5 billion to his already substantial wealth, if and when AbbVie’s $21 billion buyout goes through. But considering Duggan’s record, a multibillion-dollar payoff is to be expected. It’s the other executives and directors–who together qualify for more than $575 million–who could inspire M&A envy.
 
COO Mahkam Zanganeh, for instance, would rack up severance of $48 million, provided she’s squeezed out within two years of the merger. That includes compensation for the tax bill she’d have to pay on her windfall. More immediately–and certainly–she’ll reap a hefty $224.6 million for her shares and options, according to an SEC filing about the merger. Not bad for 6 years’ work at the biotech.
 
But that equity payoff also rewards Zanganeh for tagging Pharmacyclics as an investment target for Duggan in the first place, as her official bio points out. And a big chunk of that amount comes from the 428,281 shares Zanganeh already owns–a stake worth almost $119 million in the merger. The remaining millions come from share awards and options that were part of her compensation.
 
Pharmacyclics execs who don’t already own major stakes in the company will still enjoy quite sizable windfalls. CFO Manmeet Soni, for instance, stands to get $29.8 million for his equity, $15 million in cash for his options and $14 million for stock awards. And if he’s in line for a severance payoff almost as big as Zanganeh’s at $46 million, provided he’s terminated or leaves “for good reason,” under the company’s severance policy.
 
And Chief Commercial Officer Shawn Tomasello–who just joined Pharmacyclics last year from Celgene–is up for $28 million in severance herself. Plus almost $29 million for her equity with $26 million of that from options and share awards.
 
The moral of this story? We’d say the point is that M&A pays off for the execs involved. But that’s obvious. The real takeaway? Get a job at Duggan’s next venture.
 
By Tracy Staton
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend